Jean Coutu profit rises on gains at generic drug maker
By Allison Martell
TORONTO (Reuters) - Canadian pharmacy chain Jean Coutu Group Inc (PJCa.TO: Quote) reported a rise in adjusted quarterly earnings on Wednesday as its generic drug manufacturing subsidiary, Pro Doc, posted a double-digit gain in sales and operating income.
Prescription sales growth at Longueuil, Quebec-based Jean Coutu and rivals such as Shoppers Drug Mart Corp SC.TO have been hurt in recent years by a provincial crackdown on generic drug prices and reimbursement rules. But Jean Coutu has said Pro Doc should help boost margins over the long term.
Pro Doc's sales rose 14.0 percent to C$38.3 million ($39.2 million) in its second quarter, ended September 1, and the unit's contribution to operating income before amortization rose 25.2 percent to C$15.4 million.
"I think Pro Doc was a key strategy for them ahead of the generic drug legislation changes, and it's definitely been beneficial for the company," Canaccord Genuity analyst Derek Dley said, adding that the quarter was broadly in line with his expectations.
Ontario bans drugstores from selling their own private-label generic drugs. Canada's top court has agreed to hear a challenge to the ban by Shoppers Drug Mart.
Jean Coutu said 61.0 percent of prescriptions were for generics during its second quarter, up from 57.2 percent in the same quarter last year.
Sales at established stores, a key measure for retailers, increased 2.6 percent overall in the quarter, and 1.6 percent for non-pharmacy, or "front-end" goods.
Dley said the same-store pharmacy sales growth was a bit stronger than he had forecast, while front-end sales growth at established stores was weaker than he had expected. Continued...